Business
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov Identifier: NCT 07161999).
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS)","length":172,"tagName":"p","attribs":{}},{"type":"text","content":"Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"The ALSTARS Trial will enroll 120 ALS participants at approximately 25 centers in the United States and Canada","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov Identifier: NCT 07161999).","length":539,"tagName":"p"},{"type":"image","alt":"Coya Therapeutics Logo (PRNewsfoto/Coya Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Coya Therapeutics Logo (PRNewsfoto/Coya Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":166,"url":"https://media.zenfs.com/en/prnewswire.com/fb38d4ecdc4a3b01b49e80cb14dc14c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6YOAPSIXWRSkBXjtK9S80A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fb38d4ecdc4a3b01b49e80cb14dc14c0","width":400,"height":166}},"href":"https://mma.prnewswire.com/media/2748215/Coya_Therapeutics_Transparent_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Eligible study participants will be randomized to receive one of two different doses of COYA 302 or placebo in this 24-week, double-blind study. Participants who complete the initial placebo-controlled phase will be invited to enroll in an additional 24-week blinded extension to assess the long-term safety and efficacy of COYA 302. During this extension, all participants will receive COYA 302 a...